GFT505 is a research drug that is being developed by Genfit for the treatment of cardiometabolic diseases including diabetes insulin resistance dyslipidemia and non-alcoholic fatty liver disease (NAFLD).GFT505 is a dual PPARα/δ agonist.
This page contains content from the copyrighted Wikipedia article "GFT505"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
